Emerging as a promising breakthrough in the fight against obesity, this medication is generating considerable interest . This treatment combines effects of two known GLP-1 binding agonists, semaglutide , plus an additional glucose-dependent incretin component. Preliminary clinical findings have indicated impressive weight decrease in individuals… Read More